News | December 09, 2009

Study Shows SPECT/CT Effective in Detecting Pulmonary Embolism

December 9, 2009 – Research published in the December issue of The Journal of Nuclear Medicine (JNM) suggests SPECT, when combined with low-dose CT, may provide an accurate diagnosis for pulmonary embolism.

Pulmonary embolism is caused when a blood clot travels to a person’s lungs from another location in the body, usually the legs. Symptoms may include shortness of breath, chest pain and coughing up blood. Anyone, including people who are otherwise healthy, can develop a blood clot and subsequent pulmonary embolism. Additionally, some patients show no symptoms, making pulmonary embolism particularly difficult to diagnosis. If left untreated, the mortality rate for patients with pulmonary embolism is approximately 30 percent. The risk of death can be reduced, however, with anti-clotting medications.

“Pulmonary embolism is very difficult to diagnose clinically,” said J. Anthony Parker, M.D., Ph.D., a Beth Israel Deaconess Medical Center researcher who authored an invited perspective on the study in JNM. “Untreated, it has a high mortality rate. However, the treatment for pulmonary embolism also has serious side effects. As such, it is important not to over-treat pulmonary embolism. More accurate diagnosis, including both improved sensitivity and specificity, should result in better patient outcomes.”

In the JNM study, titled “Detection of Pulmonary Embolism with Combined Ventilation—Perfusion SPECT and Low-Dose CT: Head-to-Head Comparison with Multidetector CT Angiography,” researchers in Denmark tested the diagnostic accuracy of SPECT/CT imaging for pulmonary embolism against that of multidetector CT angiography (MDCT) alone, which is the current first-line imaging technique for diagnosing pulmonary embolism. Their study found that SPECT plus low-dose CT had a sensitivity of 97 percent and a specificity of 100 percent, whereas MDCT alone had a sensitivity of 68 percent and a specificity of 100 percent. Having an effective technique for diagnosing pulmonary embolism leads to more rapid and successful diagnosis.

In a related article also published in this month’s JNM, researchers discuss the role of SPECT in imaging pulmonary embolism and how the technology has advanced. The authors of “SPECT in Acute Pulmonary Embolism” write that there is renewed interest in this modality as the initial imaging test for pulmonary embolism as a result of improved instrumentation and improved interpretation of lung scans, as well as concerns about high radiation exposure from CT angiography, particularly to the female breast. The article supports the conclusions found by the researchers in Denmark—SPECT/CT imaging may considerably improve the diagnosis of pulmonary embolism. The article also suggests that SPECT might be useful for follow-up examinations for determining therapy’s response.

For more information: www.snm.org

Related Content

News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
Overlay Init